Pharmaceuticals

The Rise Of Advancements In Targeted And Mutation-Specific Inhibitors Driving Innovation In The Interleukin Inhibitors Is Influencing The Neulasta Market

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Neulasta Market Between 2026 And 2030?

The growth observed in the past can be linked to the increased application of chemotherapy, a rising occurrence of neutropenia induced by treatment, the accessibility of pegylated growth factors, expanded oncology supportive care protocols, and the widespread adoption of prefilled injection devices.

The anticipated growth throughout the forecast period is primarily driven by an escalating demand for convenient drug delivery systems, increasing investments in the competitive biosimilar landscape, the broadening of home-based oncology treatments, a heightened focus on patient-centric cancer care, and the rising adoption of long-acting biologic therapies.

Key trends identified for the forecast period encompass the increasing acceptance of long-acting neutropenia treatments, a growing utilization of on-body injector systems, the widening of supportive oncology care services, an increasing preference for outpatient cancer management, and a strengthened emphasis on treatment adherence.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20159&type=smp

What Key Drivers Are Fueling The Growth Of The Neulasta Market?

The increase in cancer cases is anticipated to fuel the expansion of the neulasta market. Cancer, characterized by uncontrolled cell growth that can spread throughout the body, is becoming more prevalent largely due to an aging global population, as the risk of developing the disease significantly rises with age. Neulasta, a therapy based on pegfilgrastim, plays a vital role in cancer treatment by preventing neutropenia caused by chemotherapy, encouraging white blood cell production, and thereby lowering the risk of infections for patients undergoing such treatments. For example, data from August 2024 by the Australian Institute of Health and Welfare indicates that Australia is expected to see approximately 209,000 new cancer cases by 2034, an increase from an estimated 169,000 cases in 2024, with cancer projected to be responsible for around three out of every ten deaths in 2024. Consequently, the growing occurrence of cancer will propel the neulasta market.

How Is The Neulasta Market Broken Down By Segment Categories?

The neulasta market covered in this report is segmented –

1) By Indication: Chemotherapy-Induced Neutropenia, Bone Marrow Transplantation, Other Indications

2) By Formulation: Injectable Solution, Pre-Filled Syringes Or Pens

3) By Distribution Channel: Hospitals, Oncology Clinics, Specialty Pharmacies, Home Healthcare Services

4) By End User Patients: Adult Patients, Pediatric Patients

Which Trends Are Impacting The Progress Of The Neulasta Market?

A primary trend within the neulasta market involves the creation of drug delivery solutions, such as prefilled autoinjectors, to establish a competitive advantage in the sector. Prefilled autoinjectors are self-contained injection devices preloaded with medication, designed for convenient and uncomplicated patient self-administration. For instance, in March 2023, Coherus Biosciences, a US-based biopharmaceutical company, revealed that the FDA granted approval for a single-dose, prefilled autoinjector version of its pegfilgrastim biosimilar, Udenyca (pegfilgrastim-cbqv), intended for the management and prevention of febrile neutropenia, a common issue stemming from chemotherapy. This autoinjector allows individuals to receive pegfilgrastim the day after chemotherapy, thereby diminishing the risk of febrile neutropenia. The device is characterized by push-on-skin activation for accurate and immediate administration of a full pegfilgrastim dose.

Which Players Are Present In The Neulasta Market Space?

Major companies operating in the neulasta market are Amgen Inc.

Get The Full Neulasta Market Report:

https://www.thebusinessresearchcompany.com/report/neulasta-global-market-report

Which Region Dominates The Neulasta Market By Market Share?

North America was the largest region in the neulasta market in 2025. The regions covered in the neulasta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neulasta Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neulasta-global-market-report

Browse Through More Reports Similar to the Global Neulasta Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Nematicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/nematicides-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795